FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
Executive Summary
FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market
You may also be interested in...
Boehringer Ingelheim Has Two Years To Prepare CFC-Free Combivent
FDA rejects a petition the firm had submitted in 2006 asking the agency exempt the COPD drug from a ban on ozone-depleting substances.
As Deadline For CFC Inhalers Looms, Firms Offer Incentives For HFA Switch
By the end of the year, metered dose inhalers containing chlorofluorocarbon (CFC) propellants will no longer be on the market. While consumers with asthma or chronic bronchitis will have no choice but to switch to alternative hydrofluoroalkane (HFA)-propelled products, many have been reluctant to do so
As Deadline For CFC Inhalers Looms, Firms Offer Incentives For HFA Switch
By the end of the year, metered dose inhalers containing chlorofluorocarbon (CFC) propellants will no longer be on the market. While consumers with asthma or chronic bronchitis will have no choice but to switch to alternative hydrofluoroalkane (HFA)-propelled products, many have been reluctant to do so
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: